Objective-Severe deficiency in the von Willebrand factor-cleaving protease ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13) because of mutations in the ADAMTS13 gene can lead to acute episodes of congenital thrombotic thrombocytopenic purpura (TTP), requiring prompt treatment. Current treatment consists of therapeutic or prophylactic infusions of fresh frozen plasma. However, lifelong treatment with plasma products is a stressful therapy for TTP patients. Here, we describe the use of the nonviral sleeping beauty (SB) transposon system as a gene therapeutic approach to realize lifelong expression of ADAMTS13 and subsequent protection against congenital TTP. Approach and Results-We demonstrated that hydrodynamic tail vein injection of the SB100X system expressing murine ADAMTS13 in Adamts13 −/− mice resulted in long-term expression of supraphysiological levels of transgene ADAMTS13 over a period of 25 weeks. Stably expressed ADAMTS13 efficiently removed the prothrombotic ultralarge von Willebrand factor multimers present in the circulation of Adamts13 −/− mice. Moreover, mice stably expressing ADAMTS13 were protected against TTP. The treated mice did not develop severe thrombocytopenia or did organ damage occur when triggered with recombinant von Willebrand factor, and this up to 20 weeks after gene transfer.
T hrombotic thrombocytopenic purpura (TTP) is a rare thrombotic disorder caused by deficiency in the von Willebrand factor (VWF)-cleaving protease ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13). In normal circulation, ADAMTS13 cleaves highly reactive ultralarge VWF (UL-VWF) multimers into smaller, less prothrombotic multimers preventing spontaneous platelet aggregation. Severe ADAMTS13 deficiency, caused by mutations in the ADAMTS13 gene (congenital TTP) or autoantibodies against ADAMTS13 (acquired TTP), can result in accumulation of UL-VWF multimers and intravascular deposition of VWF-and platelet-rich thrombi in the microcirculation. [1] [2] [3] During an acute episode, TTP patients typically present with thrombocytopenia, hemolytic anemia, and organ injury including cerebral, renal, and cardiac manifestations. 4, 5 Acute TTP is a medical emergency with a mortality rate as high as 90% if left untreated. In patients with congenital TTP, infusion of fresh frozen plasma (10-15 mL/kg) replenishes the missing ADAMTS13 and ameliorates disease outcome. 6, 7 Congenital TTP patients with low residual plasma ADAMTS13 activity may have frequent recurrences. 8 Knowing that each bout of TTP is life-threatening and recovery is associated with long-term deficits in health-related quality of life, 9,10 a prophylactic regimen of fresh frozen plasma is initiated in patients with frequently recurring congenital TTP. Indeed, regular plasma infusions-of which the number depends on the patient's phenotype-may prevent acute TTP episodes. [11] [12] [13] Lifelong treatment with plasma, however, is inconvenient, and administration of plasma may result in fluid overload or elicit allergic reactions to plasma proteins. The risk of viral/prion transmission also remains a major concern. Administration of recombinant ADAMTS13 would be a promising strategy, and phase I clinical trials are underway to evaluate its safety and pharmacokinetics.
Unfortunately, this treatment is still prophylactic rather than curative.
Given the severity of the disease and the limitations of fresh frozen plasma prophylaxis, gene therapy for congenital TTP would offer an attractive alternative, as correction of the underlying genetic defect would result in lifelong expression of ADAMTS13 avoiding the need for plasma infusions. Gene therapeutic approaches have been viewed as highly promising for both rare genetic diseases and more common complex disorders. The therapeutic potential of this strategy has recently been demonstrated in clinical trials for hemophilia B, 16 Leber's congenital amaurosis, 17 X-linked severe combined immunodeficiency disorder, 18 and metachromatic leukodystrophy. 19 In the TTP model, an initial preclinical study demonstrated that viral vector-mediated expression of a truncated form of ADAMTS13 protected Adamts13 −/− mice from developing TTP signs elicited by bacterial Shiga toxin. 20 Although protection from TTP was only assessed 2 weeks after gene transfer, this study provided evidence that supports the validity of a gene therapeutic approach. However, to successfully translate gene therapy into a clinical setting, a long-term expression of ADAMTS13 is required that guarantees lifelong protection of congenital TTP patients from acute TTP episodes.
To achieve long-term prevention of congenital TTP, we used the nonviral sleeping beauty (SB100X) transposon system to deliver a functional copy of the Adamts13 gene to Adamts13 −/− mice and to obtain stable, robust gene expression. This plasmid-based transposon system consists of a transposon DNA sequence and a transposase protein that excises the transposon from the donor plasmid and integrates it into the target genome ( Figure 1) . 21, 22 The SB100X system utilizes a hyperactive version of the transposase. 22 The SB transposon system has already been used to successfully integrate therapeutic genes into the host cell genome resulting in long-term transgene expression and phenotypic correction of monogenetic diseases such as hemophilia [22] [23] [24] and lysosomal storage disorders 25, 26 in preclinical animal studies. In this study, we report that delivery of the SB transposon, encoding the murine Adamts13 gene, along with an SB100X transposase to the liver of Adamts13 −/− mice can mediate long-term expression of supraphysiological levels of plasma ADAMTS13 and long-term prevention of the onset of TTP signs in Adamts13 −/− mice.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Long-Term Expression of Supraphysiological Levels of Transgene Murine ADAMTS13 in Adamts13 −/− Mice
We aimed at obtaining long-term expression of transgene murine ADAMTS13 in Adamts13 −/− mice by using the SB100X transposon system (Figure 1) . We cloned an expression cassette consisting of murine full-length Adamts13 cDNA under control of the liver-specific α 1 -antitrypsin promoter (HCRHPi) 27 into the SB transposon vector to obtain pT2/HCRHPi-ADAMTS13. To integrate the Adamts13 transgene into the mouse genome, the plasmid containing the hyperactive variant of the original transposase under control of the ubiquitous CMV promoter was used (pCMV-SB100X). 22 Plasmids were hydrodynamically injected in Adamts13 −/− mice resulting in in vivo transfection of murine hepatocytes. [28] [29] [30] In the first group of Adamts13 −/− mice (n=7), both transposon (pT2/HCRHPi-ADAMTS13) and transposase (pCMV-SB100X) plasmids were hydrodynamically injected. In this group, the integration of the murine Adamts13 cDNA into the mouse genome was promoted by the transposase (gene therapy group). In the second group of mice, Adamts13 −/− (n=7) mice were injected with a solution containing only the transposon (pT2/HCRHPi-ADAMTS13), but no transposase (control group). At 3 days post-injection, levels of transgene ADAMTS13 were remarkably high in both groups of mice (368±52% and 392±91% in the gene therapy group and in the control group, respectively; Figure 2A) . Notably, long-term follow-up of transgene ADAMTS13 expression levels indicated that transgene expression was transient in the control group, as ADAMTS13 antigen levels rapidly decreased over time (Figure 2A ). On the contrary, transgene ADAMTS13 levels remained high in the gene therapy group up to 25 weeks after gene transfer, the time point at which the experiment was ended (184±17% versus 10±2% in the gene therapy group versus the control group; Figure 2A ).
Immunohistochemical analysis of liver sections confirmed the above results. Mice with long-term and highlevel expression of transgene ADAMTS13 (gene therapy group) had a high number of ADAMTS13-expressing hepatocytes at 25 weeks post-injection ( Figure 2B , right panel). In contrast, in mice with transient ADAMTS13 transgene expression (control group), only a few ADAMTS13-positive hepatocytes were found in liver sections at 25 weeks postinjection ( Figure 2B , middle panel). Finally, we addressed whether the gene therapeutic approach induced an immune response against de novo expressed ADAMTS13. In both groups, no anti-ADAMTS13 antibodies were detected in plasma of the majority of mice ( Figure 3 ). Although we observed absorbance values above background in mice M5 and M7 in the gene therapy group and in mice M5, M6, and M7 in the control group, only in mice M5 and M6 of the control group specific anti-ADAMTS13 antibodies were detected in plasma. Indeed, only in these 2 mice, preincubation of their plasma with recombinant ADAMTS13 removed anti-ADAMTS13 antibodies resulting in a reduction of the absorbance values to background level (data not shown).
These results indicate that no profound antibody-mediated immune response against transgene ADAMTS13 was induced after gene transfer.
In conclusion, these data indicate that SB100X transposon-mediated gene delivery is a powerful technique to obtain long-term expression of supraphysiological levels of transgene ADAMTS13 in Adamts13 −/− mice. 
Long-Term Expression of Transgene ADAMTS13 Prevents the Accumulation of Prothrombotic UL-VWF Multimers in Adamts13 −/− Mice
Because of the absence of ADAMTS13 activity, prothrombotic UL-VWF multimers accumulate in Adamts13 −/− mice compared with wild-type littermates. 31, 32 Because these UL-VWF multimers are the major cause of TTP in humans, we assessed whether transgene ADAMTS13 was able to proteolyze UL-VWF multimers in Adamts13 −/− mice (Figure 4 ). At day 3 post-injection, when transgene ADAMTS13 levels were high in both groups, UL-VWF multimers were absent. The percentage of high molecular weight VWF multimers (including the UL-VWF multimers) in both the gene therapy group (29.9±0.9%; n=4) and control group (30.7±2.2%; n=5) was comparable to the percentage observed in Adamts13 +/+ mice (36.0±1.6%; n=7), which do not have UL-VWF multimers, 31 showing that UL-VWF multimers were efficiently proteolyzed by transgene ADAMTS13 (Figure 4A ). At 25 weeks post-injection however, the percentage of high molecular weight VWF multimers in the control group (39.9±1.2%; n=5) increased again to values observed in Adamts13 −/− mice (41.3±1.4%; n=8), which have UL-VWF multimers, 31 indicating that the low levels of transgene ADAMTS13 were not sufficient to digest the UL-VWF multimers ( Figure 4A and 4B). In contrast, the relative amount of high molecular weight VWF multimers was still decreased in the gene therapy group (31.7±1.3%; n=4) at 25 weeks post-injection, which is in line with the high levels of transgene Adamts13 present in these mice ( Figure 4A and 4B ).
In conclusion, SB transposon-mediated expression of the therapeutic ADAMTS13 gene leads to long-term normalization of the VWF multimer distribution in circulation and prevents accumulation of prothrombotic UL-VWF multimers in Adamts13 −/− mice.
Sleeping Beauty Transposon-Mediated Gene Therapy Prevents the Onset of TTP Signs in Adamts13 −/− Mice Up To 20 Weeks After Gene Transfer
It was previously shown that Adamts13 −/− mice develop TTP signs when they are triggered with recombinant VWF (rVWF). 14 We next investigated whether our SB100X-mediated gene therapeutic strategy could be an effective prophylactic approach to prevent acute TTP in Adamts13 −/− mice. We hydrodynamically injected 3 groups of Adamts13 −/− mice with the SB100X transposon system (gene therapy groups) to obtain long-term and high levels of transgene ADAMTS13 expression (as described in Figure 2A ). To induce TTP signs, each group was challenged with a single dose of human rVWF (2000 VWF:RCoU/kg) at different time points (1, 4, or 10 weeks after gene transfer). In parallel, we hydrodynamically injected 3 groups of Adamts13 −/− mice with a saline solution to serve as nonexpressing controls and also challenged these mice with rVWF at the 3 different time points (control groups). A single group of Adamts13 −/− mice that was hydrodynamically injected with PBS and treated with PBS instead of challenged with rVWF was used as a healthy control group. Twenty-four hours after the challenge, platelet count, plasma lactate dehydrogenase (LDH) levels (marker for tissue damage), hemoglobin levels (marker for hemolytic anemia), and weight loss were determined in all groups to assess TTP signs ( Figure 5 ). As expected, all mice in the control groups (no gene transfer) developed TTP at all time points of rVWF challenge: platelet counts were dramatically decreased (>80%; Figure 5A ), plasma LDH levels were substantially elevated ( Figure 5B ), hemoglobin levels were decreased ( Figure 5C ), and a dramatic weight loss was observed ( Figure 5D ) when compared with values observed in healthy Adamts13 −/− mice. Importantly and in stark contrast, mice of the gene therapy groups did not develop TTP signs, regardless of the time point of challenge: they did not suffer from severe thrombocytopenia ( Figure 5A ), their plasma LDH and hemoglobin levels remained within the normal range ( Figure 5B and 5C), and they did not lose weight on induction of TTP, reflecting a healthy state ( Figure 5D ). To further emphasize the long-term prophylactic efficacy of our gene therapeutic approach, an additional gene therapy group was challenged with rVWF at 20 weeks after gene transfer ( Figure 5 ). Again, mice did not develop TTP as platelet counts, plasma LDH, and hemoglobin levels remained within the normal range or did these mice lose weight. Taken together, these results demonstrate that long-term SB transposon-mediated expression of the ADAMTS13 therapeutic gene results in long-lasting prophylaxis against TTP in this animal model.
Discussion
In this study, we developed a novel integrating, nonviral gene therapy strategy to prevent congenital TTP in a mouse model. We demonstrated that SB100X-mediated gene transfer of murine Adamts13 cDNA in Adamts13 −/− mice resulted in long-term and high-level expression of the therapeutic gene. Importantly, this gene therapeutic strategy was able to normalize the VWF multimer pattern and prevent onset of acute TTP disease up to 20 weeks after gene transfer.
The SB transposon-mediated technology allowed sustained expression of high levels of transgene ADAMTS13 (184±17%) in Adamts13 −/− mice for 25 weeks post-injection (almost 6 months; the end of the study). Stable expression of high plasma ADAMTS13 antigen levels was associated with the presence of high number of ADAMTS13-expressing hepatocytes. When the SB100X transposase was absent, transgene expression rapidly dropped below WT levels within 3 weeks post-injection, resulting in a low number of ADAMTS13-expressing hepatocytes. Still, low-level transgene expression, associated with a low number of ADAMTS13-expressing hepatocytes, persisted for 25 weeks post-injection (10±2%), indicating that not all nonintegrated prokaryotic DNA was degraded or epigenetically silenced. 27, 33, 34 De novo synthesis of ADAMTS13 did not elicit a profound antibody response in the majority of the mice. This observation is in agreement with the idea that ADAMTS13 is not immunogenic. 35 Indeed, to date, alloantibody formation in congenital TTP patients treated with plasma infusions (containing exogenous ADAMTS13) has not yet been reported. Currently ongoing clinical trials using recombinant ADAMTS13 as an alternative treatment for congenital TTP will provide us with more information on the immunogenicity of ADAMTS13. Notably, expressed ADAMTS13 was biologically active in vivo, as demonstrated by the normalization of the VWF multimer pattern in Adamts13 −/− mice. Only mice expressing sustained high therapeutic ADAMTS13 levels were able to normalize the VWF multimer pattern for the whole 25-week period. These results indicate that the corresponding plasma ADAMTS13 activity was high enough to process newly secreted UL-VWF multimers. Furlan et al 36 showed that 5% plasma ADAMTS13 activity might be already sufficient to degrade the most adhesive VWF multimers into smaller forms that do not spontaneously recruit platelets in congenital TTP patients. In line with this observation, data obtained by Lotta et al 8 indicate that a small increase in residual plasma ADAMTS13 activity is sufficient to lower the risk of disease recurrence and the need for fresh frozen plasma prophylaxis in congenital TTP patients. In contrast, in the present study, we observed that the plasma ADAMTS13 activity associated with a mean antigen value of 10% (range, 2%-17%)
was not yet sufficient to alter the VWF multimer distribution. Whether this can be explained by species-specific differences in threshold ADAMTS13 levels required to normalize the VWF multimer pattern or because of synthesis of the therapeutic enzyme in heterologous cells (hepatocytes) requires further investigation. Nevertheless, our study shows that the SB100X transposon system results in expression levels of ADAMTS13 of 184±17% in Adamts13 −/− mice up to 6 months after gene transfer. Thus, it might be reasonable to assume that the SB100X system could be a proper vector able to provide stable therapeutic ADAMTS13 levels of >10% in congenital TTP patients.
Most important, transgene ADAMTS13 is shown to prevent severe thrombocytopenia and extensive organ damage in a murine model of TTP. When challenged with a high dose of rVWF, 14 Adamts13 −/− mice expressing high levels of transgene ADAMTS13 did not develop TTP signs as no profound thrombocytopenia, elevated LDH levels, decreased hemoglobin levels, and increased weight loss were observed. Notably, this protective effect was sustained for up to 20 weeks after gene transfer. To our knowledge, this is the first gene therapybased preclinical study demonstrating long-term prophylaxis for congenital TTP using a nonviral gene therapeutic approach. The use of the SB transposon technology holds high promise as it combines low cost and simplicity of naked DNA with the efficiency of gene transfer associated with retroviral vectors. SB has proven successful as a therapeutic vector in various preclinical studies demonstrating long-term gene expression in a wide range of tissues and primary cells. 37 Moreover, SB technology reached clinical level as the first phase I clinical trials using SB transposons have recently been conducted, albeit in an ex vivo gene therapy setting. 38 To transfer the SB transposon-mediated approach described in this preclinical study from bench to clinical setting, the issue of hydrodynamics-based delivery and safety must be addressed. First, although hydrodynamic tail vein injection may be an efficient delivery system in rodent animal models, the in vivo application of this technique in larger animals remains a challenge despite vigorous efforts to make the procedure clinically applicable. 39 Hence, to proceed toward clinical studies, this major hurdle needs to be overcome. Condensation of the SB plasmids with polyethylenimine or encapsulation in nanocapsules for standard intravenous infusion may be an interesting alternative to deliver the transgene into the liver. 40, 41 A second issue regarding the clinical use of the SB transposon system is the safety of SB-mediated integration. It has been shown that SB has no preference for integration into transcription units and transcriptional regulatory regions and that the majority of insertions that do occur in genes are located in introns. [42] [43] [44] Its integration site preference in mammalian cells is highly favorable compared with other transposons and integrating viral vectors, which show preferential integration into transcriptionally active sites. Interestingly, genome-wide profiling studies have recently demonstrated that SB has the highest theoretical chance of inserting the gene of interest into a safe harbor locus. 44, 45 Despite its highly favorable integration site preference in genomic safe harbor loci, however, the genotoxic risk is not zero and insertional mutagenesis after SB-mediated gene therapy cannot be excluded. Therefore, attempts are made to minimize the risk of accidental transactivation of genes. Studies have shown that engineered fusion proteins comprising zinc finger proteins and the SB transposase can be used to effectively redirect transposon insertion Figure 5 . Long-term sleeping beauty (SB100X) transposon-mediated expression of high levels of transgene ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13) prevents the onset of thrombotic thrombocytopenic purpura (TTP) signs in Adamts13 −/− mice challenged with recombinant von Willebrand factor (rVWF). Adamts13 −/− mice were injected with saline solution (control group, no gene transfer) or with plasmids coding for the SB100X system (gene therapy group) via hydrodynamic injection. Mice were subsequently challenged with a single dose of human rVWF (2000 VWF:RCoU/kg) at different wk post-hydrodynamic injection (wpi; control group and gene therapy group). Another control group (no gene transfer) was hydrodynamically injected with saline and subsequently injected with PBS instead of challenged with rVWF (non-rVWF challenged Adamts13 −/− mice). Twenty-four hours after challenge with rVWF, blood was collected and analyzed. A, Thrombocytopenia was assessed by measuring platelet counts in EDTA-treated blood using an automated cell counter. B, Tissue damage was determined by measuring lactate dehydrogenase (LDH) activity in citrated plasma using a colorimetric assay kit. C, Hemoglobin (Hb) levels were measured in EDTA-treated blood using an automated cell counter. D, Weight loss was determined by calculating the difference in weight before and 24 h after challenge with rVWF. Mean ADAMTS13 antigen levels at the indicated time points are shown. *P<0.05; **P<0.01; ****P<0.0001. ns indicates not significant; into specific sequences in the genome. 46, 47 To further reduce the genotoxic risk, one could explore the use of gene transfer strategies that retain plasmid DNA in an episomal state, such as minicircles or inclusion of "scaffold/matrix attachment regions" DNA sequences. 48, 49 In conclusion, we successfully achieved long-term therapeutic expression of full-length ADAMTS13 in Adamts13 −/− mice using the SB transposon system. This study is the first report demonstrating that a single administration of naked plasmid DNA can result in long-term correction of ADAMTS13 deficiency and prophylaxis of TTP in Adamts13 −/− mice. Considering the rate of progress in areas of vector improvement and administration, we think that the present study provides a proof of concept supporting the further development of a nonviral SB transposon-mediated gene therapy for congenital TTP in humans.
